Reed Clark, PhD

Title: Chief Science Officer, Ultragenyx Gene Therapy

Organization: Ultragenyx

Bio: Reed Clark, PhD is an experienced molecular virologist / gene therapist with extensive experience in AAV vector engineering, pre-clinical and clinical gene transfer studies and AAV vector process development and early phase clinical manufacturing. His extensive CMC regulatory experience has been acquired at Nationwide Children’s Hospital, Dimension Therapeutics, Sarepta Therapeutics and Ultragenyx Gene Therapy as part of AAV research and product development.

Gene Therapy and Gene Editing Symposium

A brief overview of the strategy guiding efforts in gene therapy and gene editing, as well as critical updates from the companies in this space. Moderated discussion included.

Jeffrey Chamberlain, PhD


Reed Clark, PhD

Chief Science Officer, Ultragenyx Gene Therapy


Olivier Danos, PhD

Chief Scientific Officer


Jennifer Hodge, PhD

Team Lead, Rare Neurology USMA


Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics